Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas
Natural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). The potential role of the immunologic (homeostatic) environm...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2010/914945 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561945513820160 |
|---|---|
| author | Luis F. Porrata David J. Inwards Ivana N. Micallef Patrick B. Johnston Stephen M. Ansell William J. Hogan Svetomir N. Markovic |
| author_facet | Luis F. Porrata David J. Inwards Ivana N. Micallef Patrick B. Johnston Stephen M. Ansell William J. Hogan Svetomir N. Markovic |
| author_sort | Luis F. Porrata |
| collection | DOAJ |
| description | Natural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). The potential role of the immunologic (homeostatic) environment affecting NK-15 recovery and survival post-APHSCT has not been fully studied. Therefore, we evaluate prospectively the cytokine profile in 50 NHL patients treated with APHSCT. Patients with an interleukin-15 (IL-15)≥76.5 pg/mL at day 15 post-APHSCT experienced superior OS and PFS compared with those who did not; median OS; not reached versus 19.2 months, P<.002; and median PFS; not reached versus 6.8 months, P<.002, respectively. IL-15 was found to correlate with (rs=0.7, P<.0001) NK-15. Multivariate analysis showed only NK-15 as a prognostic factor for survival, suggesting that the survival benefit observed by IL-15 is most likely mediated by enhanced NK cell recovery post-APHSCT. |
| format | Article |
| id | doaj-art-ecdfedebd0814c48a11ce1c9e90cdc8c |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-ecdfedebd0814c48a11ce1c9e90cdc8c2025-02-03T01:23:52ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/914945914945Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin LymphomasLuis F. Porrata0David J. Inwards1Ivana N. Micallef2Patrick B. Johnston3Stephen M. Ansell4William J. Hogan5Svetomir N. Markovic6Division of Hematology, Department of Medicine and Blood and Marrow Program, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADivision of Hematology, Department of Medicine and Blood and Marrow Program, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADivision of Hematology, Department of Medicine and Blood and Marrow Program, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADivision of Hematology, Department of Medicine and Blood and Marrow Program, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADivision of Hematology, Department of Medicine and Blood and Marrow Program, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADivision of Hematology, Department of Medicine and Blood and Marrow Program, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADivision of Hematology, Oncology Department, Mayo Clinic, 200 First Street SW, Rochester MN 55905, USANatural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). The potential role of the immunologic (homeostatic) environment affecting NK-15 recovery and survival post-APHSCT has not been fully studied. Therefore, we evaluate prospectively the cytokine profile in 50 NHL patients treated with APHSCT. Patients with an interleukin-15 (IL-15)≥76.5 pg/mL at day 15 post-APHSCT experienced superior OS and PFS compared with those who did not; median OS; not reached versus 19.2 months, P<.002; and median PFS; not reached versus 6.8 months, P<.002, respectively. IL-15 was found to correlate with (rs=0.7, P<.0001) NK-15. Multivariate analysis showed only NK-15 as a prognostic factor for survival, suggesting that the survival benefit observed by IL-15 is most likely mediated by enhanced NK cell recovery post-APHSCT.http://dx.doi.org/10.1155/2010/914945 |
| spellingShingle | Luis F. Porrata David J. Inwards Ivana N. Micallef Patrick B. Johnston Stephen M. Ansell William J. Hogan Svetomir N. Markovic Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas Clinical and Developmental Immunology |
| title | Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas |
| title_full | Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas |
| title_fullStr | Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas |
| title_full_unstemmed | Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas |
| title_short | Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas |
| title_sort | interleukin 15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non hodgkin lymphomas |
| url | http://dx.doi.org/10.1155/2010/914945 |
| work_keys_str_mv | AT luisfporrata interleukin15affectspatientsurvivalthroughnaturalkillercellrecoveryafterautologoushematopoieticstemcelltransplantationfornonhodgkinlymphomas AT davidjinwards interleukin15affectspatientsurvivalthroughnaturalkillercellrecoveryafterautologoushematopoieticstemcelltransplantationfornonhodgkinlymphomas AT ivananmicallef interleukin15affectspatientsurvivalthroughnaturalkillercellrecoveryafterautologoushematopoieticstemcelltransplantationfornonhodgkinlymphomas AT patrickbjohnston interleukin15affectspatientsurvivalthroughnaturalkillercellrecoveryafterautologoushematopoieticstemcelltransplantationfornonhodgkinlymphomas AT stephenmansell interleukin15affectspatientsurvivalthroughnaturalkillercellrecoveryafterautologoushematopoieticstemcelltransplantationfornonhodgkinlymphomas AT williamjhogan interleukin15affectspatientsurvivalthroughnaturalkillercellrecoveryafterautologoushematopoieticstemcelltransplantationfornonhodgkinlymphomas AT svetomirnmarkovic interleukin15affectspatientsurvivalthroughnaturalkillercellrecoveryafterautologoushematopoieticstemcelltransplantationfornonhodgkinlymphomas |